Results 11 to 20 of about 14,165 (152)

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer

Pharmaceutics, 2022
Neutropenia is the most frequent dose-limiting toxicity reported in patients with metastatic breast cancer receiving palbociclib. The objective of this study was to investigate the pharmacokinetic–pharmacodynamic (PK/PD) relationships for toxicity (i.e.,
Perrine Courlet, Evelina Cardoso, Carole Bandiera, Athina Stravodimou, Jean-Philippe Zurcher, Haithem Chtioui, Isabella Locatelli, Laurent Arthur Decosterd, Léa Darnaud, Benoit Blanchet, Jérôme Alexandre, Anna Dorothea Wagner, Khalil Zaman, Marie Paule Schneider, Monia Guidi, Chantal Csajka   +15 more
doaj   +1 more source

Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population

Technology in Cancer Research & Treatment, 2022
Background: Palbociclib is the most widely used cyclin-dependent kinase 4/6 inhibitor in China, but its early application efficacy on Chinese metastatic breast cancer (MBC) patients was reported deficiently.
Yusi Zhang MS, Wenlin Chen MD, Shuanglong Chen MS, Qingmo Yang MD, Zhong Ouyang MD   +4 more
doaj   +1 more source

Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer

Breast, 2021
Background: This study aimed to provide insights into the real-world use of palbociclib, dose reductions, and drug effectiveness in (older) patients with advanced breast cancer (BC).
R.K. Ismail, J. van Breeschoten, M.W.J.M. Wouters, M. van Dartel, S. van der Flier, A.K.L. Reyners, P. de Graeff, A.M.G. Pasmooij, A. de Boer, K.E. Broekman, D.L. Hilarius   +10 more
doaj   +1 more source

P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib.

PLoS ONE, 2019
The P16 (CDKN2Aink4a) gene is an endogenous CDK4/6 inhibitor. Palbociclib (PD0332991) is an anti-CDK4/6 chemical for cancer treatment. P16 is most frequently inactivated by copy number deletion and DNA methylation in cancers. It is well known that cancer
Paiyun Li, Xuehong Zhang, Liankun Gu, Jing Zhou, Dajun Deng   +4 more
doaj   +1 more source

Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance

Cancer Biology & Medicine, 2019
Objective Lack of effective therapies remains a problem in the treatment of oral squamous cell carcinoma (OSCC), especially in patients with advanced tumors.
Nur Syafinaz Zainal, Bernard Kok Bang Lee, Zheng Wei Wong, Iuan Sheau Chin, Pei San Yee, Chai Phei Gan, Kein Seong Mun, Zainal Ariff Abdul Rahman, J. Silvio Gutkind, Vyomesh Patel, Sok Ching Cheong   +10 more
doaj   +1 more source

FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells

Cells, 2021
Resistance to CDK4/6 inhibitors (CDKis) is emerging as a clinical challenge. Identification of the factors contributing to CDKi resistance, with mechanistic insight, is of pivotal significance.
Qiong Cheng, Zhikun Ma, Yujie Shi, Amanda B. Parris, Lingfei Kong, Xiaohe Yang   +5 more
doaj   +1 more source

Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer

Patient Preference and Adherence, 2023
Nicole M Engel-Nitz,1 Mary G Johnson,1 Michael P Johnson,1 Ashley S Cha-Silva,2 Samantha K Kurosky,2 Xianchen Liu2 1Optum, Eden Prairie, MN, 55344, USA; 2Pfizer Inc, New York, NY, 10017, USACorrespondence: Nicole M Engel-Nitz, HEOR | Optum Life Sciences,
Engel-Nitz NM, Johnson MG, Johnson MP, Cha-Silva AS, Kurosky SK, Liu X   +5 more
doaj  

The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer

Current Oncology, 2022
Background: Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, in combination with letrozole or fulvestrant has been demonstrated to prolong the progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human ...
Fulbert Fu, Jessica Kano, Julia Ma, Mera Guindy   +3 more
doaj   +1 more source

Exploration of Therapeutic Targets Using CDK4 Inhibitors for Head and Neck Mucosal Melanoma. [PDF]

Otolaryngol Head Neck Surg
Abstract Objective Mucosal melanoma (MM) is an extremely aggressive malignant tumor in the head and neck region associated with a poor prognosis. In the present study, we conducted cell proliferation assay and western blotting using cell lines derived from MM and the immunohistochemical analysis of pathological MM tissues to identify novel therapeutic ...
Hattori T, Fujii M, Ueda T, Ishikawa A, Mine Y, Xu B, Suehiro T, Hattori M, Tahara H, Sato Y, Chikuie N, Taruya T, Hamamoto T, Ishino T, Takeno S.   +14 more
europepmc   +2 more sources

Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells

Cancer Cell International, 2020
Background Aberrant activity of cell cycle proteins is one of the key somatic events in non-small cell lung cancer (NSCLC) pathogenesis. In most NSCLC cases, the retinoblastoma protein tumor suppressor (RB) becomes inactivated via constitutive ...
Lindsey R. Conroy, Pawel Lorkiewicz, Liqing He, Xinmin Yin, Xiang Zhang, Shesh N. Rai, Brian F. Clem   +6 more
doaj   +1 more source